Get the Stockscreener App
1.28
1.92%
-0.02
Phio Pharmaceuticals Corp stock is traded at $1.28, with a volume of 129.61K.
It is down -1.92% in the last 24 hours and down -39.57% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$1.30
Open:
$1.3
24h Volume:
129.61K
Relative Volume:
0.05
Market Cap:
$14.35M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.1569
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-17.74%
1M Performance:
-39.57%
6M Performance:
-30.71%
1Y Performance:
-42.31%
1-Day Range:
$1.26
$1.31
1-Week Range:
$1.26
$1.64
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.28 | 14.35M | 0 | -11.66M | -11.09M | -8.156 |
|
ARGX
Argen X Se Adr
|
916.75 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.89 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
196.17 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
378.72 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.49 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress - MarketScreener
Phio Pharmaceuticals (NASDAQ: PHIO) to Present INTASYL siRNA at Advanced Therapies USA - Stock Titan
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsJuly 2025 Institutional & Fast Momentum Stock Entry Tips - newser.com
Will Phio Pharmaceuticals Corp. (44R1) stock profit from AI boomWeekly Trade Recap & High Conviction Investment Ideas - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesIndex Update & Low Volatility Stock Recommendations - newser.com
Can Phio Pharmaceuticals Corp. hit a new high this monthBond Market & Safe Capital Growth Tips - newser.com
Is Phio Pharmaceuticals Corp. stock attractive for retirement portfoliosWeekly Stock Report & Safe Capital Growth Trade Ideas - newser.com
Is Phio Pharmaceuticals Corp. stock supported by strong fundamentalsPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
Is Phio Pharmaceuticals Corp. (44R1) stock included in top ETFsJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Will Phio Pharmaceuticals Corp. stock outperform tech sector in 2025Market Risk Report & Verified Momentum Stock Watchlist - Fundação Cultural do Pará
How Phio Pharmaceuticals Corp. stock performs after earningsJuly 2025 Action & Entry Point Confirmation Alerts - Fundação Cultural do Pará
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Newsfile
Can Phio Pharmaceuticals Corp. rally from current levelsJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
What drives Phio Pharmaceuticals Corp 44R1 stock priceMACD Histogram Signals & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Top chart patterns to watch in Phio Pharmaceuticals Corp.Market Performance Report & Long-Term Capital Growth Ideas - newser.com
Best data tools to analyze Phio Pharmaceuticals Corp. stockEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Developing predictive dashboards with Phio Pharmaceuticals Corp. data2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Using economic indicators to assess Phio Pharmaceuticals Corp. potentialEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
Analyzing Phio Pharmaceuticals Corp. with multi timeframe charts2025 Price Targets & Weekly High Momentum Picks - newser.com
Its Stock Has Paid Off Big Time For Phio Pharmaceuticals Corp - setenews.com
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 - Newsfile
Phio’s INTASYL PH-762 wins immunomodulatory solution of the year By Investing.com - Investing.com South Africa
Phio’s INTASYL PH-762 wins immunomodulatory solution of the year - Investing.com
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program - Newsfile
Phio Pharma (NASDAQ: PHIO) to present Phase 1b PH-762 skin cancer results at SITC - Stock Titan
Phio Pharmaceuticals Exercises Warrants for $13.4 Million - TipRanks
Is Phio Pharmaceuticals Corp. stock in correction or buying zoneJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
How Phio Pharmaceuticals Corp. stock benefits from tech adoptionGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
How currency fluctuations impact Phio Pharmaceuticals Corp. stockWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):